Steven G Potkin Selected Research

Nausea

12/2015	A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.
11/2002	Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven G Potkin Research Topics

Disease

70	Schizophrenia (Dementia Praecox) 06/2022 - 02/2002
19	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2002
15	Tardive Dyskinesia 01/2021 - 10/2002
12	Psychotic Disorders (Schizoaffective Disorder) 01/2020 - 04/2002
8	Weight Gain 01/2015 - 10/2002
7	Bipolar Disorder (Manic Depressive Psychosis) 02/2018 - 04/2002
5	Movement Disorders (Movement Disorder) 01/2021 - 09/2007
5	Treatment-Resistant Schizophrenia 10/2020 - 09/2007
5	Dementia (Dementias) 01/2020 - 01/2002
4	Dyskinesias (Dyskinesia) 10/2020 - 11/2005
4	Psychomotor Agitation (Akathisia) 12/2015 - 07/2006
4	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2015 - 04/2002
4	Sleepiness 12/2015 - 04/2002
3	Inflammation (Inflammations) 01/2020 - 01/2016
3	Cognitive Dysfunction 01/2020 - 02/2009
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2016 - 04/2006
3	Dizziness (Lightheadedness) 07/2006 - 04/2002
2	Down Syndrome (Down's Syndrome) 01/2020 - 01/2017
2	Huntington Disease (Huntington's Disease) 05/2018 - 02/2013
2	Atrophy 05/2018 - 01/2018
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2017 - 01/2016
2	Nausea 12/2015 - 11/2002
2	Dystonia (Limb Dystonia) 12/2015 - 10/2013
2	Vomiting 12/2015 - 11/2002
2	Dyspepsia (Indigestion) 12/2015 - 02/2013
2	Genetic Predisposition to Disease (Genetic Predisposition) 07/2015 - 08/2010
2	Mental Disorders (Mental Disorder) 01/2015 - 04/2014
2	Pain (Aches) 10/2013 - 11/2011
2	Tachycardia (Tachyarrhythmias) 02/2013 - 07/2006
2	Sleep Deprivation 08/2009 - 01/2008
2	Tobacco Use Disorder (Nicotine Dependence) 04/2009 - 01/2004
1	Brain Diseases (Brain Disorder) 01/2019
1	Chorea (Rheumatic Chorea) 05/2018
1	Disease Progression 01/2018
1	Mood Disorders (Mood Disorder) 01/2016
1	Basal Ganglia Diseases (Basal Ganglia Disease) 12/2015

Drug/Important Bio-Agent (IBA)

39	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 08/2002
11	Biomarkers (Surrogate Marker)IBA 06/2022 - 05/2010
8	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 02/2002
8	Clozapine (Clozaril)FDA LinkGeneric 01/2020 - 10/2002
8	Aripiprazole (Abilify)FDA Link 01/2018 - 07/2003
8	Risperidone (Risperdal Consta)FDA LinkGeneric 11/2013 - 04/2002
8	ziprasidone (Geodon)FDA Link 02/2013 - 05/2003
6	Proteins (Proteins, Gene)FDA Link 11/2018 - 06/2010
6	Pharmaceutical PreparationsIBA 02/2017 - 02/2002
6	Haloperidol (Haldol)FDA LinkGeneric 12/2015 - 04/2002
6	Quetiapine Fumarate (Seroquel)FDA Link 04/2013 - 04/2002
5	Paliperidone Palmitate FDA Link 01/2019 - 10/2015
4	Glutamic Acid (Glutamate)FDA Link 01/2020 - 08/2002
4	Amyloid (Amyloid Fibrils)IBA 01/2020 - 08/2010
4	Lurasidone Hydrochloride FDA Link 12/2015 - 11/2011
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2021 - 01/2017
3	Olanzapine (Zyprexa)FDA Link 01/2020 - 02/2004
3	Biological ProductsIBA 01/2020 - 01/2004
3	Antidepressive Agents (Antidepressants)IBA 02/2018 - 01/2008
3	Therapeutic UsesIBA 03/2016 - 07/2006
3	asenapine FDA Link 11/2013 - 10/2007
3	iloperidone FDA Link 02/2013 - 04/2008
3	Nicotine FDA Link 04/2009 - 01/2004
2	EnzymesIBA 10/2020 - 11/2005
2	aripiprazole lauroxilIBA 01/2019 - 12/2017
2	Tetrabenazine (Nitoman)FDA Link 05/2018 - 11/2013
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2012 - 05/2009
2	salicylhydroxamic acid (SHAM)IBA 10/2012 - 07/2006
2	Rivastigmine (Exelon)FDA LinkGeneric 02/2009 - 01/2006
2	ProlactinIBA 10/2007 - 07/2006
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2007 - 01/2003
1	DysbindinIBA 01/2021
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 10/2020
1	Serotonin (5 Hydroxytryptamine)IBA 01/2020
1	3-carboxamido-4-hydroxynaltrexoneIBA 01/2020
1	Amyloid beta-PeptidesIBA 01/2020
1	brexpiprazoleIBA 01/2020
1	ErbB-4 ReceptorIBA 01/2019
1	cariprazineIBA 01/2019
1	Neuregulin-1 (Neuregulin 1)IBA 01/2019
1	5-HT1A Serotonin ReceptorIBA 01/2019
1	3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)IBA 11/2018
1	deutetrabenazineIBA 05/2018
1	Environmental BiomarkersIBA 01/2018
1	perlecanIBA 01/2018
1	ApolipoproteinsIBA 01/2018
1	Dopamine D2 Receptor AntagonistsIBA 01/2017
1	Cell Adhesion MoleculesIBA 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	GlucocorticoidsIBA 01/2016
1	Biogenic Amines (Biogenic Amine)IBA 01/2016
1	EndocannabinoidsIBA 01/2016
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2016
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2016
1	P-2 (P 2)IBA 01/2016
1	TESIBA 04/2014

Therapy/Procedure

7	Therapeutics 05/2018 - 04/2002
3	Injections 12/2017 - 01/2016
3	Activities of Daily Living (ADL) 08/2006 - 01/2002
2	Transcranial Magnetic Stimulation 10/2012 - 07/2006
1	Secondary Prevention 01/2019
1	Drug Therapy (Chemotherapy) 02/2017
1	Combined Modality Therapy 01/2017
1	Long-Term Care 01/2016